Results 111 to 120 of about 101,527 (239)

Immunotyping the Tumor Microenvironment Reveals Molecular Heterogeneity for Personalized Immunotherapy in Cancer

open access: yesAdvanced Science, EarlyView.
This study develops TMEclassifier, a machine‐learning tool that classifies cancers into three distinct subtypes—Immune exclusive (IE), immune suppressive (IS), and immune activated (IA)—which exhibit significant heterogeneity and necessitate customized therapeutic strategies.
Dongqiang Zeng   +27 more
wiley   +1 more source

SCORT–Cas13d Nanotherapy Precisely Targets the ‘Undruggable’ Transcription Factor HoxB13 in Metastatic Prostate Cancer In Vivo

open access: yesAdvanced Science, EarlyView.
SCORT–Cas13d–pre‐gHoxB13 lipid nanoparticles precisely deliver Cas13d mRNA and guide RNAs to metastatic prostate tumors in the liver, knocking down the “undruggable” transcription factor HoxB13. This approach suppresses metastatic tumor growth, extends mouse survival, and does not induce major organ toxicity or immune activation, offering a safe and ...
Zhifen Cui   +15 more
wiley   +1 more source

Differential effects of selective and non-selective cyclooxygenase inhibitors on fecal microbiota in adult horses. [PDF]

open access: yesPLoS One, 2018
Whitfield-Cargile CM   +5 more
europepmc   +1 more source

Bioengineered Tumor‐Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance

open access: yesAdvanced Science, EarlyView.
The upregulated CCL24 in CRC liver metastasis promotes the formation of inflammatory tumor‐associated fibroblast subsets and induces resistance to bevacizumab therapy. Downregulation of CCL24 significantly increased sensitivity to antiangiogenic therapy in CRC mouse model. Hence, a novel therapeutic target is identified for patients with CRC with liver
Junjiang Wang   +7 more
wiley   +1 more source

Communications Among Neurocytes in Parkinson's Disease Regulated by Differential Metabolism and Blood‐Brain Barrier Traversing of Chiral Gold Cluster‐MOF Integrated Nanoparticles

open access: yesAdvanced Science, EarlyView.
This study have loaded chiral gold nanoclusters onto the inner and outer surfaces of ZIF and uncovers the biodistribution, metabolic variances, and therapeutic mechanism of chiral nanoparticles, providing deep insights into the nanobiological effects of chiral anti‐inflammatory nanomedicines in PD therapy for future clinical transformation.
Junyang Chen   +7 more
wiley   +1 more source

Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling [PDF]

open access: yes, 2003
ATTOUB, S   +11 more
core   +1 more source

Genetically Engineered IL12/CSF1R‐Macrophage Membrane‐Liposome Hybrid Nanovesicles for NIR‐II Fluorescence Imaging‐Guided and Membrane‐Targeted Mild Photothermal‐Immunotherapy of Glioblastoma

open access: yesAdvanced Science, EarlyView.
A theranostic nanoplatform is formulated with NIR‐II emissive lipophilic cyanine dye IRC18 to intercalate into genetically engineered IL12/CSF1R‐macrophage membrane‐liposome hybrid nanovesicles, which assists to achieve blood–brain barrier crossing, glioblastoma targeting, NIR‐II fluorescence imaging, image‐guided membrane‐targeted mild photothermal ...
Pengfei Chen   +10 more
wiley   +1 more source

Author Correction: Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice. [PDF]

open access: yesCommun Biol
Mortensen R   +9 more
europepmc   +1 more source

Identification of CD38high Monocyte as a Candidate Diagnostic Biomarker and Therapeutic Target for Sepsis

open access: yesAdvanced Science, EarlyView.
This study uncovers that CD38high monocytes discriminate sepsis and sterile inflammation and are associated with 28‐day mortality in bacterial sepsis. Targeting CD38 therapy reduces inflammatory response in monocytes and in sepsis mice model. Mechanistically, CD38‐HIF‐1α/glycolysis/MGO loop exacerbates sepsis‐induced immune dysregulation.
Ning Hua   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy